AR Yan, M Naunton, GM Peterson… - Journal of clinical …, 2020 - mdpi.com
Background: Antiplatelet medications such as aspirin and clopidogrel are used following thrombotic stroke or transient ischemic attack (TIA) to prevent a recurrent stroke. However …
MS Oh, KH Yu, JH Lee, S Jung, C Kim, MU Jang… - Neurology, 2016 - AAN Enterprises
Objectives: To investigate whether aspirin resistance is associated with initial stroke severity and infarct volume, using diffusion-weighted imaging (DWI) in patients with acute ischemic …
X Hou - Journal of International Medical Research, 2024 - journals.sagepub.com
Strokes are the leading cause of death in most regions of the world. Epoxidase inhibitors include the drug aspirin (acetylsalicylic acid). Aspirin is widely used as first-line treatment for …
X Cheng, NC Xie, HL Xu, C Chen, YJ Lian - Oncotarget, 2017 - ncbi.nlm.nih.gov
To explore the correlation of aspirin resistance (AR) with clinical stroke severity and infarct volume using diffusion-weighted imaging (DWI) in 224 Chinese ischemic stroke patients …
A Wiśniewski, J Sikora, A Sławińska, K Filipska… - Journal of Clinical …, 2020 - mdpi.com
Background: Excessive platelet activation and aggregation plays an important role in the pathogenesis of ischemic stroke. Correlation between platelet reactivity and ischemic …
C Coignion, M Poli, S Sagnier, G Freyburger… - European …, 2015 - karger.com
Background: Stroke occurrence despite chronic antiplatelet drug (APD) treatment is frequent. We aimed at evaluating the relevance of platelet aggregation testing in the …
A Wiśniewski, J Sikora, K Filipska… - Neurologia i …, 2019 - journals.viamedica.pl
Aim. Excessive activation and platelet aggregation play important roles in the aetiopathogenesis of cerebral ischaemia. The aim of this study was to assess the …
M Morton, K Kubiak-Balcerewicz, A Sarnowska… - Folia …, 2021 - termedia.pl
Results Eighty patients were included to the study, fifty one patients to the acute stroke/TIA group (ASG) and 29 patients to the control group (CG). There was no statistically significant …
Background: High on-treatment platelet reactivity or its equivalent—resistance to the antiplatelet agent—significantly reduces the efficacy of the therapy, contributing to a …